NCT00406380

Brief Summary

Evaluation of efficacy of Intravitreal Injection of Bevacizumab in patients with Yuxtafoveal Telangiectasias

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Sep 2006

Shorter than P25 for phase_3

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2006

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2006

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2006

Completed
29 days until next milestone

First Submitted

Initial submission to the registry

November 30, 2006

Completed
4 days until next milestone

First Posted

Study publicly available on registry

December 4, 2006

Completed
Last Updated

May 30, 2024

Status Verified

May 1, 2024

Enrollment Period

Same day

First QC Date

November 30, 2006

Last Update Submit

May 29, 2024

Conditions

Telangiectasis

Keywords

TelangiectasiasLeakageBevacizumabTelangiectasias secondary to Branch Retinal Vein Occlusion (BRVO)Idiopathic juxtafoveal retinal telangiectasias

Outcome Measures

Primary Outcomes (3)

  • Best corrected Visual Acuity

  • Fluorescein Angiogram: Leakage

  • Optical Coherence Tomography: Retinal thickness

Interventions

BevacizumabDRUG
Intravitreal injection of BevacizumabPROCEDURE

Eligibility Criteria

Age40 Years - 70 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with Telangiectasias secondary to Branch Retinal Vein Occlusion
  • Patients with Idiopathic Juxtafoveal Retinal Telangiectasias

You may not qualify if:

  • Diabetic Retinopathy and Diabetic Macular Edema
  • Hypertensive Retinopathy
  • Choroidal Neovascularization

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Asociacion para Evitar la Ceguera en Mexico

Mexico City, Mexico City, 04030, Mexico

Location

MeSH Terms

Conditions

Telangiectasis

Interventions

Bevacizumab

Condition Hierarchy (Ancestors)

Vascular DiseasesCardiovascular Diseases

Intervention Hierarchy (Ancestors)

Antibodies, Monoclonal, HumanizedAntibodies, MonoclonalAntibodiesImmunoglobulinsImmunoproteinsBlood ProteinsProteinsAmino Acids, Peptides, and ProteinsSerum GlobulinsGlobulins

Study Officials

  • Veronica Kon-Jara, MD

    Asociación para Evitar la Ceguera en México

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
phase 3
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
FACTORIAL
Sponsor Type
OTHER

Study Record Dates

First Submitted

November 30, 2006

First Posted

December 4, 2006

Study Start

September 1, 2006

Primary Completion

September 1, 2006

Study Completion

November 1, 2006

Last Updated

May 30, 2024

Record last verified: 2024-05

Locations

ME(1)